Figure 2.
Cumulative incidence of csCMVi by day 180 in adult CBT recipients receiving letermovir prophylaxis or historic control patients managed with preemptive therapy. No recipient of extended-duration letermovir prophylaxis (n = 28) developed csCMVi in the first 180 days post-CBT. The day 180 cumulative incidence of csCMVi in historic control patients (n = 62) was 82% (95% CI, 73-92).

Cumulative incidence of csCMVi by day 180 in adult CBT recipients receiving letermovir prophylaxis or historic control patients managed with preemptive therapy. No recipient of extended-duration letermovir prophylaxis (n = 28) developed csCMVi in the first 180 days post-CBT. The day 180 cumulative incidence of csCMVi in historic control patients (n = 62) was 82% (95% CI, 73-92).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal